RecruitingPhase 1NCT07172971
Neuromuscular
Becker Muscular Dystrophy
Also known as BMD, Becker MD
Becker Muscular Dystrophy is an X-linked recessive disorder caused by in-frame mutations in the DMD gene, resulting in reduced but partially functional dystrophin protein. Unlike Duchenne MD, patients typically remain ambulatory past age 16
ORPHA:98895 ↗Gene DMDPrevalence 1 in 18,000 male birthsOnset Childhood to early adulthood (later than Duchenne)X-linked recessive
61
studies recruiting now
as of 7 Sept 2026
501
studies registered in total
as of 7 Sept 2026
11
countries with a recruiting site
as of 7 Sept 2026
17 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT07587242
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
RecruitingNCT07092540
The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy
RecruitingNot applicableNCT07766980
Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
RecruitingPhase 2NCT07287189
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 61 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Becker Muscular Dystrophy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: Duchenne Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Becker Muscular Dystrophy
Becker Muscular Dystrophy is an X-linked recessive disorder caused by in-frame mutations in the DMD gene, resulting in reduced but partially functional dystrophin protein. Unlike Duchenne MD, patients typically remain ambulatory past age 16 and the course is more variable, ranging from mild proximal weakness to severe cardiac and respiratory involvement. Cardiomyopathy is a leading cause of morbidity and mortality in BMD.
Common clinical features
Proximal limb-girdle pattern muscle weaknessCalf pseudohypertrophyDilated cardiomyopathyExercise intolerance and myalgiaElevated serum creatine kinase (often >1000 IU/L)Respiratory insufficiency in advanced diseaseCognitive or learning difficulties in a subset
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 approved treatment and 10 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Delandistrogene Moxeparvovec (Delandistrogene moxeparvovec component of elevidys)
Phase 2Pemirolast
Phase 2(-)-Epicatechin
Phase 2Sildenafil
Phase 2Sevasemten
Phase 2Ataluren (Translarna)
Phase 2Vamorolone (Agamree)
Phase 2Givinostat
Phase 1/2Stamulumab
+ 2 more in development
Before you apply
Things trial teams commonly ask about for Becker Muscular Dystrophy. Not eligibility rules; those are set by each study.
- Genetic testing confirming an in-frame DMD deletion or duplication is typically required; exon-level results from multiplex ligation-dependent probe amplification (MLPA) are preferred
- Cardiac trials specifically target BMD due to cardiomyopathy prevalence — cardiac MRI with ejection fraction data is frequently a screening prerequisite
- Ambulatory status and 6-minute walk distance (6MWD) are primary stratification variables; document these with a physiotherapist before applying
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).